| Similar Articles |
|---|
 |
Pharmaceutical Executive
October 1, 2005
Jill Wechsler |
Washington Report: Antivirals: Meeting a World of Need The international fight against AIDS requires drugs -- and policy.   |
Pharmaceutical Executive
September 1, 2011 |
The Power of PDP Can cooperative ties between Big Pharma, NGOs, government, and international organizations pay the freight in making the fight against neglected diseases a permanent fix in global health? |
Pharmaceutical Executive
February 1, 2009
Joanna Breitstein |
Vaccines for All The world is suffering. But just over the horizon is a new access equation that could speed innovative vaccines to where they're needed most. |
Pharmaceutical Executive
February 1, 2006
Joanna Breitstein |
Breath of Hope: TB in Africa For the first time in decades, the pharmaceutical industry has tuberculosis drugs in the pipeline. But it will take more than new pills to solve the problem. |
Pharmaceutical Executive
September 1, 2013
William Looney |
High Noon For Hot Markets Fading growth, overstretched governments, and a global governance backlash against pharma business are turning up the heat on the performance of emerging country markets. |
Salon.com
June 1, 2001
Daryl Lindsey |
The AIDS-drug warrior Outspoken AIDS-drug activist Jamie Love says pharmaceutical companies must be forced to yield their patents to save hundreds of thousands of lives. Is he a visionary -- or a dangerous radical? |
BusinessWeek
August 5, 2010
Bennett & Randall |
AIDS Drugs Flow to the Third World Drugmakers, once blasted for their practices, are slashing prices and licensing AIDS drugs for free to nonprofits or local manufacturers in developing countries. |
Pharmaceutical Executive
September 1, 2010 |
Is There a Balm for Gilead? A new leader, a big acquisition, and a bold investment in HIV may all be in the works at Gilead. But what will it take to restore the glory days? |
Pharmaceutical Executive
July 3, 2007
Jill Wechsler |
Washington Report: Vaccines for Everyone New vaccines can be good business and a huge boon to public health. But the challenge is to establish prices that ensure global access, and to bring necessary medications to third-world countries. |
Pharmaceutical Executive
September 1, 2006
Jill Wechsler |
Washington Report: New Partnerships Pursue Old Diseases A new wave of collaborations between industry, non-profits, and government seeks affordable treatments for neglected diseases around the world. |
Bio-IT World
Dec 2005/Jan 2006
Salvatore Salamone |
Gates, Clinton Address Global Health Summit The conference brought together leaders in business, government, medicine, public philanthropic groups, and the arts to address and develop solutions to the world's heath crises. |
Pharmaceutical Executive
May 1, 2012 |
Country Report: South Africa In just the past few years, South Africa has hit several key economic benchmarks demonstrating the country's upward trajectory. |
Pharmaceutical Executive
April 1, 2011 |
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition. |
Pharmaceutical Executive
September 1, 2013
Stan Bernard |
The Drug Combination Competition Companies are leveraging combinations of drugs and other products to gain competitive advantage and market share. |
Pharmaceutical Executive
September 1, 2011 |
Filling Front and Center in the Fight against TB Dr. Mel Spigelman, President and CEO of the TB Alliance, discusses the organization's priorities in developing treatments for tuberculosis. |
Pharmaceutical Executive
September 1, 2012
Stan Bernard |
The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model. |
Pharmaceutical Executive
May 1, 2011
Cacciotti & Clinton |
12th Annual Pharm Exec 50 Pharm Exec's annual run-down of the world's biggest pharma companies. |
Pharmaceutical Executive
July 30, 2007
Walter Armstrong |
Tibotec Gets AIDS With a new wave of "resistant to resistance" HIV drugs, a record of consistent innovation, and a dynamic partnership with AIDS activists, Tibotec is in it to win it. And end it. |
The Motley Fool
April 21, 2009
Brian Orelli |
Reworking the Broken R&D Model When it comes to drug development, it's becoming increasingly clear that competition isn't always the best thing for the industry. Collaborations will help bring drugs to the market more cheaply. |
Pharmaceutical Executive
April 1, 2014
Subramanian et al. |
"Market-Based" Price Controls In India? Three strategic implications for pharma pricing strategies in India. |
Salon.com
March 19, 2001
Ben Barber |
Fighting the plague The World Trade Organization steps into Africa's AIDS crisis, creating incentives for pharmaceutical companies to give some of their drugs away. |
Chemistry World
January 6, 2015
Sarah Houlton |
Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion. |
The Motley Fool
March 14, 2008
Stephen Albainy-Jenei |
The War on (the Cost of) Drugs Pharmaceutical companies could be hurt by countries disregarding drug patents. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
The Next Wave: Pharm Exec's 2011 Pipeline Report 42 of the best new drugs in development or parked at the FDA |
Chemistry World
July 11, 2012
Ling Wang |
China Targets Patented Drugs with Law Change China has altered its licensing laws to allow domestic pharmaceutical companies to make cheap generic copies of patented drugs under certain circumstances. |
BusinessWeek
April 18, 2005
Manjeet Kripalani |
India: Bigger Pharma Tougher patent protection laws are spurring rapid growth in new drug research across India. |
Salon.com
May 1, 2001
Daryl Lindsey |
Amy and Goliath A first-year law student brought a giant pharmaceutical to its knees. But will her victory for South Africa's AIDS sufferers deprive the world of new medicines? |
The Motley Fool
December 14, 2006
Stephen Albainy-Jenei |
Merck Gets Punk'd by Thailand Thailand issues a compulsory license to manufacture a generic version of Merck's patented AIDS drug. This is an act of humanitarian aid, but it is also an avenue for price and profit erosion worldwide. |
Chemistry World
December 17, 2015
Sarah Houlton |
Pills, prices and politics Pharmaceutical pricing has been a hot topic in 2015, with the drugs bill continuing to rise as costly new treatments reach the market. |
Chemistry World
August 15, 2012 |
The latent threat of tuberculosis Although TB was close to being eradicated in the developed world, it is a major problem in developing countries. With drug-resistant strains on the increase, Clare Sansom outlines the latest in the fight against this killer disease |
Pharmaceutical Executive
January 1, 2011 |
The Steep, Slow Climb A survey of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade. |
Chemistry World
December 22, 2011
Sarah Houlton |
Pharma braces for patent cliff impact It remains to be seen quite how far Lipitor sales will fall. Ranbaxy has six months of exclusivity for generic competition. |
The Motley Fool
June 30, 2009
Brian Orelli |
A Cocktail for Drug Investors Drug cocktails aren't just for alchemists anymore. In many diseases they've become big business, and pharmaceutical investors would be smart to pay attention. |
The Motley Fool
November 30, 2010
Brian Orelli |
A Witty Response to Pharma's R&D Dilemma According to GlaxoSmithKline CEO Andrew Witty, the pharmaceutical industry is a mess. That's the basic gist of his opinion piece in The Economist. |
Pharmaceutical Executive
August 1, 2013
Joseph Saba |
New Rules for a New Africa Declining revenue growth in the United States and Europe have sent pharmaceutical companies in search of opportunities in the BRICs and other emerging economies. Now, companies are finally turning their attention to Africa. |
Chemistry World
August 4, 2008
Pete Mitchell |
Vaccine failures shake up HIV research Prospects for an HIV vaccine have receded with the July decision by the US government National Institutes of Health (NIH) to cancel trials of its main vaccine candidate. |
Pharmaceutical Executive
June 1, 2011 |
Emerging Pharma Leaders 2011 Meet 2011's Emerging Pharma Leaders. Can these 30 trendsetters build competitive scale from scarcity? |
Pharmaceutical Executive
December 1, 2005
Ron Feemster |
The PharmExec 2005 Pipeline Report Dry? Not quite. Instead of 1990s-style blockbusters, pharma's new molecules are niche drugs, cancer treatments and -- at last -- innovative mechanisms for troublesome targets: Acomplia [rimonabant] by Sanofi-Aventis... AMG 162 [denosumab] by Amgen... etc. |
BusinessWeek
April 1, 2010
Bennett & Randall |
Will an AIDS Pill a Day Keep the Virus Away? Drugmaker Gilead is betting the one-pill PrEP treatment will slow the virus' spread - as are some of the world's top health agencies and philanthropists. |
Pharmaceutical Executive
July 3, 2007 |
Harbingers of Change What to watch, and watch out for, in the bottom half of '07. The IMS Health Editorial Board identifies what it believes are the key events that will impact the global pharmaceutical market in the near future. |
CFO
Kris Frieswick |
Clinical Trials A new kind of pricing pressure puts pharmaceutical CFOs in an unfamiliar role: evangelist... |
Chemistry World
December 22, 2010
Sarah Houlton |
Fines, Flu and an Uncertain Future It was another tough year for the pharma industry, with downsizing, pricing concerns and the impending expiration of patents on many products. But some of the biggest headlines were caused by eye-watering fines dished out in the US. |
Pharmaceutical Executive
January 1, 2012
Jill Wechsler |
New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation. |
Pharmaceutical Executive
December 1, 2010
Zhu Shen |
China 2020: Walled In No More Pharma sets the pace for China's ambitious new innovation agenda |
Pharmaceutical Executive
November 1, 2014
Casey McDonald |
Advocacy Beat: Progress in Global Access to TB Drugs Treatment Action Group reaches a milestone in improving access to much-needed treatments for tuberculosis. |
The Motley Fool
January 21, 2010
Brian Orelli |
Here's That Critical Merck Info You Missed Announcing clinical trial failures in a FAQ? Really? |
The Motley Fool
January 7, 2010
Brian Orelli |
Pfizer Strides Farther Into Generics Pfizer's new look might be just what the doctor ordered. |
Pharmaceutical Executive
December 1, 2011
Ben Comer |
Pharm Exec's 2012 Pipeline Report It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle? |
| Knowledge@Wharton |
Encouraging the Development of Drugs for Poor, not Just Rich, Nations The current system rewards research into diseases that afflict rich countries, but creating new medicines for the rest of the world and finding ways to pay for them will demand new partnerships, according to panelists at the recent conference "Pharmaceutical Innovation in a Global Economy." |
Pharmaceutical Executive
July 10, 2014
Fitzpatrick & Mohan |
Vaccines: Fire in the Cold Chain It's only recently that vaccine producers experienced the commercial returns commensurate with vaccines: long record of positive public health performance. |
